Work

Postresection Antiviral Treatment in Hepatocellular Carcinoma Patient with Undetected Hepatitis B virus DNA

Year: 2025

Type: article

Abstract: A BSTRACT Hepatocellular carcinoma (HCC) is a lethal cancer, and resection therapy is the main curative treatment. Nonetheless, the recurrence rate is the main obstacle, and postresection antiviral therapy use in those with low-level HBV DNA is still a dilemma. We report the case of a 62-year-old male with Hepatitis B virus (HBV) related-HCC who underwent liver resection and continued to take nucleoside analog (NA) in a previously undetectable HBV DNA. The administration of antiviral therapy in these patients increased survival rates for 5 years, with time to first recurrence of 2 years postresection. The use of NA is associated with virus replication suppression and inflammation improvement. NA therapy effectively reduces the risk of HCC recurrence following curative therapy and improves survival rates even with low levels of viremia.

Source: Biomolecular and Health Science Journal

DOI: 10.4103/bhsj.bhsj_20_24

Authors: Meridian Nuarwenty, Budi Widodo, Sovia Salamah

Institutions: Universitas Airlangga, University Medical Center Groningen, University of Groningen

Language: English

Topic: Hepatitis B Virus Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4411784507

FWCI:

Cites: 15

Cited by:

Related to: 10